The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

Let’s take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

What is Microdosing?

Microdosing is the practice of consuming a very low, sub-hallucinogenic dose of a psychedelic substance, such as psilocybin or LSD. While scientific literature contains minimal research, there is plenty of anecdotal evidence to support the practice but the handful of high-quality studies that do exist paint a mixed picture of microdosing efficacy.

In 2018, the Imperial College of London conducted the first placebo-controlled study of microdosing practices. Participants received either a psychedelic or placebo and completed online surveys and cognitive tasks at regular intervals. The results showed improvements in both the psychedelic and placebo groups with no significant differences between them.

Other researchers believe that microdosing may still offer tangible benefits. Maastricht University researchers in the Netherlands conducted their own small-scale placebo-controlled study and found beneficial effects on mood and attention for some participants that couldn’t be explained by the placebo effect. They suggest that timing could be an important factor.

The same researchers from Maastricht University measured brain-derived neurotrophic factor (BNDF)—a protein that affects brain plasticity—and found an increase a few hours after microdosing psychedelics in blood tests. These findings suggest that there is some kind of physiological factor at play with microdosing practices.

 Ensuring the Right Dose

The varying effects of microdosing practices could be the results of varying metabolic rates and drug delivery mechanisms. For instance, capsule-based forms of microdosing involve swallowing a pill that is subject to second-pass metabolism in the liver. Sublingual delivery mechanisms, on the other hand, quickly move to the brain. 

Revive Therapeutics Ltd. (CSE: RVV) is building an intellectual property portfolio around psychedelic drug delivery. After acquiring Psilocin Pharma Corp., the company partnered with Complete Phytochemical Solutions and signed a sponsored research deal with the University of Wisconsin-Madison to develop new delivery methods for psychedelic substances.

The company’s dissolvable oral strips could be especially beneficial for microdosing, delivering between one and 20 milligrams of natural or synthetic psilocybin with rapid onset that bypasses liver metabolism. The company’s other products targeting both psychedelics and cannabinoids include lozenges, gels, creams and transdermal patches. 

While many companies undergo expensive clinical trials, the company’s innovative delivery systems could see a faster path to commercialization as California, Oregon and other states start to legalize psychedelics for personal use. These efforts could open the door to widespread microdosing practices to realize cognitive and other mental health benefits.

Looking Ahead

Investors interested in the psychedelics space may want to consider companies focused on microdosing practices since they could represent a nearer-term path to commercialization. Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a prime example with its dissolvable oral strip delivery system for psilocybin microdosing.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s at the helm.

Let’s take a look at what sets Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF)

management team apart and why its board members represent a strong vote of confidence in the team and business over the long-term.

Experienced Management

Delic was founded by veterans from the cannabis industry—another highly-regulated industry that went from zero to billions of dollars in just a handful of years.

Co-Founders Matt and Jackee Stang were executives at High Times, a leading counterculture publication that became the voice for the cannabis industry. In fact, the monthly magazine had a circulation of over 500,000 copies an issue, rivaling Rolling Stone, and its website attracted 500,000 to five million users each month by 2014 as cannabis took off.

Matt Stang was a previous owner and operator of High Times, was instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with all corners of the cannabis community for two decades, he helped found Delic two years ago as one of the first psychedelic corporations. His expertise in marketing, branding, business development and product viability and will prove invaluable as he shapes the company’s vision and path.

Most recently, John Coleman, Ph.D., former President of Anandia Labs, a cannabis biotech company focused on genetics and analytics, was hired as VP of Business Development. With a foot in both corporate and scientific worlds, Dr. Coleman is well-equipped to head up the company’s business development efforts as it looks to enter new vertical markets.

The company also recently hired Zak Garcia, former CMO of Bulletproof Inc., maker of the well-known Bulletproof® Coffee brand, as its Chief Marketing Officer. Mr. Garcia is a highly sought-after marketing and leadership strategist that helped grow Bulletproof® Coffee to over $250 million in revenue—experience that will help bring Delic to the next level of growth.

Click here to receive an investor presentation and corporate updates

Renowned Billion-Dollar Backers

Delic’s management team is supported by an impressive Board of Directors that reads like a who’s who of success stories in cannabis and other industries.

Paul Rosen was a co-founder of PharmaCan Capital Corp. and served as its first President and CEO.

Kraig Fox was a Senior Managing Director at Guggenheim Partners and later served as President and CEO of High Times. The involvement of these industry icons alone represents a big vote of confidence in the management team.

Mr. Rosen and Mr. Fox are joined by entrepreneur and venture capitalist Martin Tobias, finance veteran Sashko Despotovski and Dr. Markus Roggen, Founder and CEO of Complex Biotech Discovery Ventures. On the board of advisors, investors will find best-selling author Shep Gordon, Apollo Neuroscience Founder Dave Rabin and other leading voices.

The company’s well-known and respected board members provide a vote of confidence in the management team, valuable connections to grow its businesses and expertise that can be called upon to help make strategic decisions. With a wide range of expertise and disciplines, these team members could be invaluable in building long-term shareholder value.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is well-equipped to grow with its veteran executive team and its star-studded board of directors and advisors. With the right team in place, the company has been actively making acquisitions to become a strategic and diversified player in the nascent psychedelics industry today and well into the future. 

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

“Patent angemeldet” ist ein Ausdruck, mit dem Sie wahrscheinlich vertraut sind. Sie haben gesehen, wie es auf der Seite eines Dinges im Einkaufszentrum gestempelt wurde, oder Sie haben es in der Fernsehsendung gehört, die Sie gerade anschauen, und Sie denken sich: „Wow, ich wünschte, ich könnte etwas erfinden, das jeder für wirklich cool hält.“ Die meisten von uns haben irgendwann den gleichen Gedanken gehabt. Leider ist es, wie die meisten Dinge im Leben, komplizierter, etwas zu erfinden, das Leben verändert und dann die Erfindung zu patentieren, als Sie vielleicht denken, insbesondere im Bereich der Biotechnologie und Pharmazie. Jemand im Fernsehen hat vielleicht ein paar Jahre und ein paar Tausend Dollar damit verbracht, etwas in seiner Garage zu schaffen, aber diese Kosten sind im Vergleich zu den Kosten, die für die Erforschung, den Test und die Herstellung neuer Medikamente erforderlich sind, gering. Pharmaunternehmen benötigen 5 bis 15 Jahre und mehr als eine Milliarde Dollar an Forschungs- und Entwicklungskosten, um neue Medikamente zu entwickeln. Allein ist das ein komplizierter und kostspieliger Prozess, der im Fall von natürlich gewonnenen Arzneimitteln durch bestimmte Richtlinien, die für Patente für Naturprodukte spezifisch sind, weiter erschwert wird.

Anforderungen an die Patentierbarkeit

Damit eine Erfindung patentiert werden kann, muss sie drei Anforderungen erfüllen: Sie muss neuartig, nützlich und erfinderisch sein (nicht offensichtlich). Jedes Jahr machen Pharmaunternehmen fundierte Vermutungen, erstellen und untersuchen Tausende von Molekülen und finden manchmal eine Handvoll, die eine Krankheit behandeln könnten. Diese Moleküle erfüllen gelegentlich die drei oben genannten Anforderungen: Sie sind ein neues Molekül, sie können nützlich sein, da frühe Tests zeigen, dass sie sich möglicherweise positiv auf unsere Gesundheit auswirken und sie sind erfinderisch, weil sie eine nicht offensichtliche Anwendung eines Prozesses oder einer Idee sind, die bereits existiert, aber in dieser Situation so noch nicht angewendet wurden. In der Vergangenheit hatten Natur und Evolution Millionen von Jahren Zeit, um einige glückliche Fehler zu machen, die eine Vielzahl von Pflanzen hervorgebracht haben, die Stoffe mit medizinischen Eigenschaften enthalten. Während ihre wenigen Erfolge zur Behandlung von Krankheiten angenommen und genutzt wurden, machen dieselben Erfolge diese Substanzen unoriginell und können daher nicht als neue Zusammensetzungen patentiert werden.

Aber Myriad hat doch etwas Natürliches patentiert?

Obwohl natürlich vorkommende Verbindungen nicht zum Patentschutz berechtigt sind, gab es eine Zeitspanne, in der das US-Patentamt Patente für DNA-Sequenzen (Gene) erteilte. Myriad Genetics Inc. erhielt Patente sowohl für die genetischen Sequenzen der BRCA1- und BRCA2-Gene als auch für die Methoden zur Diagnose von Mutationen, die Frauen für Brust- und Eierstockkrebs prädisponieren. Die Monopolisierung von BRCA1- und BCRA2-Gentests war für das Unternehmen von großem Vorteil, bis seine Patente 2013 angefochten wurden. In der Klage wurde argumentiert, dass die genetischen Sequenzen Naturprodukte seien und damit die Patentansprüche ungültig machten und Myriad andere nicht daran hindern könne, Gentests für Frauen anzubieten. Der Fall wurde schließlich vor den obersten Gerichtshof der USA gebracht, wo entschieden wurde, dass eine natürlich vorkommende DNA-Sequenz genau wie ein natürliches Molekül nicht patentierbar ist. Diese Entscheidung zwang das US-Patentamt, neue Leitlinien für Patentprüfer zu veröffentlichen, die bei der Überprüfung von Patenten auf der Basis natürlich abgeleiteter Moleküle zu berücksichtigen sind.

Klicken Sie hier, um eine Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Drei Fragen, die beim Versuch, ein Naturprodukt zu patentieren, zu beantworten sind

Nachdem Gene und natürliche Moleküle nicht patentfähig, dann doch und dann wieder nicht patentierbar waren, wurden sie schließlich als patentierbar angesehen, wenn sie bestimmte Kriterien erfüllten. Auf den ersten Blick sehen die vom US-Patentamt veröffentlichten Richtlinien nicht kompliziert aus. Das Dokument enthält einen Flowchart mit drei Fragen. Diese Fragen bewerten, ob die Erfindung ein neues Verfahren oder eine neue Sache ist; ob es sich auf natürliche Prinzipien, Phänomene oder Produkte bezieht; und ob sich die Erfindung wesentlich von der in der Natur gefundenen Version unterscheidet. Die Fragen 1 und 2 sind am einfachsten zu beantworten und disqualifizieren unter anderem die natürlich in psychedelischen Pilzen vorkommenden Substanzen Psilocybin und Psilocin sofort. Die Beantwortung von Frage 3 erfordert die Berücksichtigung von 12 zusätzlichen Faktoren. Bei der Betrachtung dieser 12 Faktoren sprechen 6 Faktoren für die Patentberechtigung und 6 dagegen, wobei die Mehrheit die Antwort auf die dritte Frage diktiert. Diese 12 Faktoren helfen einem Patentprüfer bei der Entscheidung, ob sich eine natürlich abgeleitete Erfindung signifikant von ihrem natürlichen Verwandten unterscheidet.

Wie MagicMed natürliche Moleküle patentiert

Neue Forschungen haben gezeigt, dass die von Pilzen produzierten psychedelischen Moleküle therapeutische Eigenschaften zur Behandlung von psychischer Gesundheit und Hirnstörungen besitzen können. Die Zusammensetzung dieser Naturstoffe kann nicht patentiert werden. Strukturell und funktionell veränderte Derivate dieser Moleküle können jedoch patentrechtlich geschützt werden, wenn sie die strengen Anforderungen erfüllen und als wesentlich anders angesehen werden als die in Pilzen vorkommenden. Die Prozesse, die erforderlich sind, um veränderten Derivate herzustellen und zu synthetisieren, die diese hohe Messlatte erfüllen, stellen für die meisten Unternehmen eine Herausforderung dar. Das Team von MagicMed ist jedoch führend bei pflanzlichen molekularen Derivaten. Dieses Fachwissen war entscheidend für den Erfolg von MagicMed bei der Umwandlung derselben nicht patentierbaren natürlichen Moleküle in Pilzen in Derivate, die neuartig, nützlich und erfinderisch sind. Diese Modifikationen haben sichergestellt, dass die therapeutischen Wirkungen der Elternmoleküle verstärkt und auf eine bestimmte Indikation ohne die negativen Nebenwirkungen spezialisiert werden.

Die in der Derivatbibliothek enthaltene Sammlung von Medikamentenkandidaten von MagicMed – treffend Psybrary genannt – stützt sich auf Patentanmeldungen, die die Zusammensetzung und Synthesemethode für Millionen potenzieller Moleküle beanspruchen, die von den klassischen oder natürlichen Psychedelika inspiriert sind, sich jedoch in einzigartiger Weise von diesen unterscheiden. Das Unternehmen ist zuversichtlich, dass Entwicklungspartner den Wert dieser Verbindungsbibliotheken erkennen werden, auch weil jedes neue Molekül 20 Jahre Patentschutz genießen wird. Dieser Zeitraum sollte den Partnern die erforderliche Zeit geben, um präklinische und klinische Tests mit ihrem bevorzugten Molekül durchzuführen und es durch die Arzneimittelentwicklungspipeline führen, um letztendlich Zugang zum Markt zu erlangen und eine solide Rendite für ihre F & E-Investitionen zu erzielen.

Klicken Sie hier, um eine Investorenpräsentation und Unternehmensaktualisierungen zu erhalten

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund (“ETF”). The ETF will begin traded on the Neo Exchange on January 26, 2021.

Havn Life is one of seventeen companies that met the minimum requirements of listing within the ETF. The ETF is managed by Horizons ETF Management, one the largest ETF providers in Canada, with over CDN $16 billion in assets under management across 93 ETFs. Horizons also brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries.

Inclusion into an ETF is an important milestone for Havn Life’s investors and stakeholders. The ETF will bring additional exposure to potential new investors, as well as generate value for existing shareholders.

Tim Moore remarked, “Our team is excited to be included in Horizons Psychedelics ETF, which will allow Havn Life to become available to a wider audience of the investment community. We continue to work to provide added shareholder value to our stakeholders.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds.

Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram, and Youtube.

Contact:
Investor Relations: [email protected], (604) 687-7130
Media: [email protected]rgence-creative.com, (647) 896-8078

Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

SOURCE: Havn Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/625396/Havn-Life-Sciences-Announces-Inclusion-in-First-Psychedelic-Exchange-Traded-Fund

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions.

MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, shortcut its commercialization timeline via a Research Contract and Facilities Use Agreement with the University of Calgary to support the development of its PsybraryTM.

Let’s take a closer look at this agreement and what it means for the company as it gears up to go public in the middle of next year.

Agreement Provides Research Support

MagicMed has been focused on the development of the PsybraryTM, a library of psychedelic molecular derivatives that it hopes to license to partners to commercialize. Since these molecules are patentable—unlike natural compounds—with unique properties, they are ideally suited for pharmaceutical companies to develop into psychedelic-based mental health therapies.

The company’s recent agreement with the University of Calgary will provide it with further scientific and laboratory support to accelerate development of the PsybraryTM and shortcut its commercialization timeline. Through the agreement, the company will be able to leverage new state of the art equipment and draw upon world-class expertise at the university.

“The additional resources that the University of Calgary is providing to MagicMed complement and enhance our strengths,” says Dr. Joseph Tucker, CEO MagicMed. “This collaboration places MagicMed in a position to expand the breadth and depth of the psychedelic derivatives contained in the MagicMed PsybraryTM.”

Click here to receive and investor presentation and corporate updates

Psybrary’s Unique Business Model

MagicMed’s team has been creating and patenting new molecular derivatives over the past 25 years with a focus on opiates, cannabinoids and ephedra. In particular, Chief Scientific Officer Dr. Peter Facchini is a recognized leader in the development of new molecular derivatives with over 160 scientific papers and 20 patents in the field.

MagicMed’s Place within the Process – Source: Investor Presentation

The PsybraryTM forms the basis of a unique business model capable of generating high-margin recurring revenue over time. By licensing derivative molecules, the company plans to generate licensing fees, milestone payments and blue-sky royalties when commercial products are launched into the market—all with minimal capital expenditures.

In addition to high margin revenue, the company works with a number of commercialization partners, which provides built-in diversification. Investors don’t have to bet all of their money on the success of one clinical trial, but rather, invest in a number of clinical trials run by partners where MagicMed retains the potential for royalty income.

Click here to receive and investor presentation and corporate updates

Looking Ahead

MagicMed Industries has shortcut its commercialization timeline with University of Calgary agreement. Over the next year, the company plans to expand its PsybraryTM with new patent filings, onboard its first partner, achieve a positive cash flow and publicly list during the first or second quarter—enabling retail investors to participate in the upside potential.

Investors may want to keep an eye on the company as it gears up for a public listing due to its multiple indications, partnership strategies, de-risked revenue model with blue sky potential and its conservative capital markets strategy geared toward generating near-term positive cash flow and long-term shareholder value.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen und zwei Breakthrough Therapie Bezeichnungen, sind Unternehmen, die Kapital beschaffen, um die  Multi-Milliarden-Dollar Märkte der psychischen Gesundheit zu revolutionieren.

Werfen wir einen Blick auf den Vormarsch psychedelischer Therapien, ihr Potenzial zur Behandlung, die massiven Märkte der psychischen Gesundheit und warum MagicMed Industries Inc. gut positioniert ist, mit seinem einzigartigen Buisnessmodell von dem entstehenden Markt zu profitieren.

Psychedelika gehen Mainstream

Psychedelika haben sich schnell von Randprodukypten zum Mainstream in Forschung und Entwicklung entwickelt. Das Imperial College of London, die University of California-Berkeley und Johns Hopkins haben alle psychedelische Forschungszentren etabliert, während die Food-and Drug Administration (FDA) den Status einer Breakthrough Therapie an zwei Psychedelika in aktiven klinischen Studien vegeben hat. Neben Forschung und Entwicklung haben die Kapitalmärkte einen unstillbaren Appetit für psychedelische Gelegenheiten gezeigt. Compass Pathways Inc. (NASDAQ: CMPS) hat sich nach seinem Börsengang an der NASDAQ verdoppelt und erreichte eine Marktkapitalisierung von mehr als eine Milliarde Dollar trotz des Anfangsstadiums seiner Bemühungen.

Die Kombination von Forschungsinteressen und Kapital generiert den perfekten Sturm, der nötig ist, um Millionen von Menschen, die an psychischen Problemen leiden, zu helfen und den

Markt für psychische Gesundheit zu transformieren. Diese Märkte im Wert von Milliarden von Dollar pro Jahr sind mit herkömmlichen Pharmazeutika und anderen Behandlungsmöglichkeiten unterversorgt.

Klicken Sie hier, um weitere Informationen zu Investitionen in Psychedelika zu erhalten

Massive Märkte für geistige Gesundheit

Mehr als ein Viertel der Amerikaner über 18 Jahren leiden unter einer diagnostizierbaren Störung der psychischen Gesundheit pro Jahr und ungefähr 17.3 Millionen Erwachsene haben mindestens eine heftige depressive Phase durchgemacht, laut Johns Hopkins. Tatsächlich sind  psychische Störungen eine der Top-Ursachen für Behinderung in etablierten Volkswirtschaften weltweit.

Psychedelika haben einen einzigartigen Wirkmechanismus, der eine wichtige Rolle bei der Behandlung einer große Anzahl dieser psychiatrischen Erkrankungen spielen könnte. Während Antidepressiva und andere Medikamente der psychischen Gesundheit seit geraumer Zeit angewandt werden und Milliarden von Dollar Umsatz pro Jahr generieren, ist ihre Wirksamkeit für die Mehrheit der Patienten fraglich.

Zum größten Potenzial für Psychedelikamärkte gehören:

Über diese Märkte hinaus gibt es eine Vielzahl von medizinischen Bereichen, die von  herkömmlichen Therapeutika unterversorgt sind und in denen Psychedelika eine wichtige Rolle spielen könnten. Aufkommende Forschung legt nahe, dass Psychedelika einen einzigartigen Wirkmechanismus bieten, der sich von konventionellen Behandlungen im Bereich psychischer Gesundheit unterscheidet und sichere permanente Alternativen bietet.

In Psychedelika investieren

Eine wachsende Zahl öffentlicher und privater Unternehmen zielt auf den psychedelischen Bereich ab, beispielsweise Compass Pathways Inc. (NASDAQ: CMPS) und Red Light Holland Corp (CSE: TRIP). Während viele dieser Unternehmen klinische Studien mit dem Ziel der Entwicklung anerkannter Pharmazeutika durchführen, haben andere einen auf dem Markt einzigartigen Ansatz. MagicMed Industries zielt darauf ab, führend in der Entwicklung neuer psychedelischer Molekülderivate zu werden. Während Psilocybin und andere natürlich vorkommenden psychedelische Moleküle nicht patentierbar sind, können Derivate verändert werden, um spezifische Ziele (z.B. weniger psychoaktive Effekte) zu erfüllen und Pharmazeutik-Unternehmen bessere Vermarktung zu ermöglichen.

Klicken Sie hier, um weitere Informationen zu Investitionen in Psychedelika zu erhalten

Das Unternehmen baut die Psybrary auf, in der sich eine Reihe psychedelischer Moleküle befinden, deren Lizenzen es an pharmazeutische oder Biotechnologieunternehmen vergibt. Durch die Lizenzierung der Moleküle, die das Unternehmen plant, generiert es Zahlungen auf der Grundlage klinischer Meilensteine und laufender Lizenzgebühren für jedes anerkannte pharmazeutische Produkt, was hohe Margen und wiederkehrenden Umsatz schafft. Zusätzlich zu den attraktiven Einnahmequellen haben Aktionäre Zugriff auf eine vielfältige Auswahl an Partnern, die eine breite Aufstellung in der Branche erlauben. Hoffnungen des Managements, 2020 erste Partner zu finden, werden zu positivem Cashflow  2021 und möglicherweise sogar zu diversifizieren Konsumgütern im Jahre 2022 führen.

Blick in die Zukunft

Die Psychedelikaindustrie könnte einige Segmente des Marktes für psychische Gesundheit mit Milliarden von Dollar Jahresumsatz nachhaltig verändern. Während viele Unternehmen einen klinische Ansatz auf dem Markt verfolgen, zielt MagicMed Industries darauf ab, ein führendes Unternehmen in der Entwicklung psychedelischer Derivat-Moleküle zu werden, deren Lizenzen es an pharmazeutische Unternehmen vergibt.

Investoren sollten das Unternehmen im Auge behalten, während es sich anschickt, im ersten oder zweiten Quartal des nächsten Jahres an die Börse zu gehen.

Weitere Informationen finden Sie auf der Website des Unternehmens oder indem Sie die Präsentation für Investoren downloaden.

Kontakt von MagicMed:

Beziehungen mit den Investoren

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The psychedelics industry is poised to become a nearly $7 billion market by 2027, according to Data Bridge Market Research, driven by the potential to revolutionize the treatment of mental health disorders. While investors have many options in the space, the best positioned companies are combining delivery mechanisms with novel compounds to create IP strategies.

Let’s take a look at why delivery mechanisms matter and how Cybin Corp. is leveraging sublingual delivery to revolutionize psychedelic therapies.

What Are Delivery Mechanisms?

Most pharmaceuticals come from natural sources—and the same is true for both cannabis and psychedelics. Of course, the final product that people pick up from the pharmacy is typically pill, capsule, spray, suppository or other delivery mechanism.

Delivery mechanisms play an important role in ensuring the bioavailability and optimal delivery of pharmaceutical compounds. For instance, extended release tablets slowly release an active pharmaceutical ingredient, or API, over time rather than all at once. These capabilities can be transformative for chronic pain relief therapies by making a once-a-day option.

Aside from convenience and performance, delivery mechanisms may be required for any efficacy. The most common problem experienced by some pharmaceuticals is first-pass metabolism in the liver. While it’s possible to simply increase the dosage, there are many instances where high doses become toxic, making a delivery mechanism essential.

Benefits of Delivery Mechanisms

The most obvious benefit of a delivery mechanism is that it improves the performance of a pharmaceutical compound or makes it safe to use. But aside from these benefits, there are several other reasons to develop innovative delivery mechanisms.

Delivery mechanisms are a common way to patent natural compounds or extend expiring patents. While patients and consumers can still access cheap natural compounds or legacy products, these delivery mechanisms typically improve the efficacy of the compound or offer other benefits that may encourage commercial adoption.

The development of delivery mechanisms themselves also represents unique intellectual property. Investors in these companies benefit from both a potentially efficacious and unique delivery, as well as the ability to leverage the same delivery technology across a wide range of different compounds—or even the ability to license it to others.

Cybin’s Psychedelic Approach

Cybin Corp. is focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions.

Watch Cybin CEO Doug Drysdale discuss the innovative delivery mechanism:

Click here to learn more about investing in Cybin and receive corporate updates

The company’s wholly owned subsidiary, Serenity Life Sciences, has developed a fast-acting sublingual delivery strip technology that provides both improved bioavailability and greater convenience for patients. In particular, sublingual delivery offers fast access to the bloodstream and bypasses second-pass metabolism in the liver.

The unique delivery mechanism is being used in a Phase II randomized, parallel group, bioequivalence study of psilocybin for the treatment of Major Depressive Disorder. If successful, the company could become one of the first life science companies to launch a fully approved psilocybin product targeting depression.

Watch CEO Doug Drysdale outline the company’s clinical trial strategy:

Click here to learn more about investing in Cybin and receive corporate updates

Looking Ahead

Cybin Corp. could become one of the first life sciences companies to commercialize psilocybin for the treatment of depression. With an innovative delivery mechanism, the company developed a patentable product with potentially significant advantages over other forms of psilocybin, creating an attractive commercial opportunity.

The company plans to go public through a reverse-takeover of Clarmin Explorations on the TSX Venture exchange. In connection with the going public transaction, the company plans to raise a minimum of $14 million and a maximum of $21 million to fund its ongoing research and development activities.

For more information, visit the company’s website or download the investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.